12results about How to "Reduce non-specific binding" patented technology

The invention discloses a confining liquid capable of effectively reducing the adsorption effect of an ELISA (enzyme-linked immunosorbent assay) enzyme-free plate. The confining liquid is a phosphate Tween buffer solution containing 2% of bovine serum albumin, the phosphate Tween buffer solution contains 0.05% of Tween-20, and the concentration of phosphate in the phosphate Tween buffer solution is 10 mM; % is the mass percentage content.

The invention relates to the technical field of nucleic acid detection, and discloses a universal automatic nucleic acid extraction module based on a rotating structure, which comprises a liquid storage layer and a runner layer which are arranged up and down, the nucleic acid extraction module is internally provided with a lysate chamber, a binding liquid chamber, a magnetic bead chamber, a pre-cleaning liquid chamber, a post-cleaning liquid chamber, an eluent chamber, a sample treatment chamber, a waste liquid chamber and a sample loading chamber; a valve core is arranged in the sample treatment cavity, a sample treatment cavity piston is arranged in a core cavity of the valve core, and a liquid transfer opening communicated with the core cavity is formed in the side wall of the core cavity; the top surface of the flow channel layer is respectively provided with flow channels communicated with the sample treatment chamber corresponding to the lysis solution chamber, the combination solution chamber, the magnetic bead chamber, the front cleaning solution chamber, the rear cleaning solution chamber, the eluent chamber, the waste liquid chamber and the sample loading chamber; the valve element rotates around the axis of the valve element and can communicate with different flow channels. The liquid flow channel is convenient to switch, the structure is simpler, the assembly is simpler, the cost is lower, the size is smaller, and the weight is lighter.

The present invention belongs to the field of biomedicine, and specifically relates to a method for capturing a nano antibody containing a human IgG1-CH1 domain, and separating and purifying an IgG1 antibody, Fab or F(ab')2 using the nano antibody. Because VHH is a single-domain antibody that is very stable, it is expected to have very low immunogenicity compared to bacterial surface proteins such as protein A and protein G, and is independent of the IgG-Fc domain to capture the antibody, which can effectively solve the problem of light chain dropout. The antibody can specifically recognize the IgG1-CH1 domain with high affinity. The affinity chromatography medium with the anti-human IgG1-CH1 domain nano antibody of the present invention as a ligand can achieve the purification of IgG1 and its Fab or F(ab')2 fragments, and has a very broad application prospect.

The invention discloses a single-domain antibody for resisting African swine fever virus E165R protein as well as a screening method and application of the single-domain antibody, and relates to the technical field of bioengineering. The invention provides a single-domain antibody for resisting African swine fever virus E165R protein and a specific amino acid sequence, and also provides a gene for coding the single-domain antibody, an expression vector comprising the gene and a phage for expressing the gene, and the single-domain antibody for resisting the African swine fever virus E165R protein is applied to African swine fever virus immunological detection. The single-domain antibody provided by the invention has relatively strong specificity, high sensitivity and strong neutralizing activity, and can be used for immunological detection of daily epidemic diseases and system construction of future epidemic disease prevention and control.

The invention discloses a single-domain antibody with neutralizing activity for resisting African swine fever virus E165R protein as well as a screening method and application thereof, and relates to the technical field of bioengineering. The invention discloses a single-domain antibody with neutralizing activity for resisting African swine fever virus E165R protein. The amino acid sequence of the single-domain antibody is shown as SEQ ID NO. 1. The invention also discloses a gene for coding the single-domain antibody, a nucleotide sequence of the gene, an expression vector comprising the gene, a bacteriophage for expressing the gene, application of the single-domain antibody with neutralizing activity for resisting the African swine fever virus E165R protein to African swine fever virus immunological detection, and a screening method of the single-domain antibody. The single-domain antibody developed by the invention has strong specificity, high sensitivity and strong neutralizing activity, and can be used for immunological detection of daily epidemic diseases and system construction of future epidemic disease prevention and control.

The application relates to the field of molecular biology and discloses a LAMP primer group and a kit for detecting influenza A virus H1N1. The primer group comprises an outer primer pair, an inner primer pair and a loop primer pair; the outer primer pair comprises a forward outer primer with a nucleotide sequence as shown in SEQ ID NO. 1 and a reverse outer primer with a nucleotide sequence as shown in SEQ ID NO. 2; the inner primer pair comprises a forward inner primer with a nucleotide sequence as shown in SEQ ID NO. 3 and a reverse inner primer with a nucleotide sequence as shown in SEQ ID NO. 4; and the loop primer pair comprises a forward loop primer with a nucleotide sequence as shown in SEQ ID NO. 5 and a reverse loop primer with a nucleotide sequence as shown in SEQ ID NO. 6. The primer group has good thermal stability, is suitable for 70 DEG C high-temperature LAMP amplification, reduces non-specific binding, and has good sensitivity and specificity.

This invention discloses a preparation process for a targeted drug delivery system based on the synergistic effect of Lamp2b and IMTP, comprising the following steps: constructing cells overexpressing the Lamp2b-IMTP fusion protein, culturing cells overexpressing the Lamp2b-IMTP fusion protein, thereby obtaining the targeted drug delivery system. The Lamp2b / IMTP synergistic targeted drug delivery system obtained by this invention allows for the specific accumulation of drugs in target cells, such as tumor cells, achieving precise drug delivery. The fundamental localization role of Lamp2b: Lamp2b is a naturally occurring transmembrane protein on the surface of exosomes, responsible for mediating the "initial recognition" between exosomes and recipient cells, ensuring that the delivery system, with exosomes as the core carrier, can be effectively recognized and bound by cells, avoiding rapid clearance by the body as a "foreign substance."

The utility model provides a kind of traditional Chinese medicine extraction preparation filtering device, it is related to traditional Chinese medicine preparation technical field.The filtering device includes: vertical filter tank body, its top and bottom are separately provided with liquid inlet pipe and liquid outlet pipe;First filter screen, it is set in vertical filter tank body inner chamber, and the inner chamber of vertical filter tank body is divided into raw liquid storage cavity and clear liquid storage cavity by vertically;Deslagging assembly, including gravity type deslagging pipe and low-frequency ultrasonic wave generating structure, one end of gravity type deslagging pipe is communicated with raw liquid storage cavity, and the other end extends to the outside of vertical filter tank body, and low-frequency ultrasonic wave generating structure is set on the lateral wall of vertical filter tank body;And magnetic field generating structure, including magnetic nano-particle adding pipe and multiple different diameter annular electromagnet, magnetic nano-particle adding pipe is communicated with raw liquid storage cavity, and multiple annular electromagnets are concentrically set in the bottom of first filter screen.The present application effectively alleviates the problem that viscous substance fills pore in conventional device, and resistance increases suddenly.

This application relates to the technical field of bioassay, specifically disclosing a combined detection kit for pepsinogen I and pepsinogen II and its application. The disclosed combined detection kit for pepsinogen I and pepsinogen II includes: a sample pad, a conjugate pad, a coating membrane, and an absorbent pad; the coating membrane is an NC membrane coated with antibody; the conjugate pad is prepared by pretreating and drying a fiber membrane, followed by spraying time-resolved fluorescent microspheres labeled with antibody; the pretreating solution is a solution of pH 8.0-8.4 + 8-12mM BS + 0.8-1.2% BSA + 0.8-1.2% PEG4000 + 0.02-0.03% surfactant + 4-6% sucrose. Using the detection kit and method provided in this application for the combined detection of pepsinogen I / pepsinogen II exhibits high sensitivity, accuracy, and repeatability.

The present application relates to a kind of fluorescent enhancement composition and fluorescent enhancement liquid for tyramide signal amplification system.The fluorescent enhancement composition of the present application includes enhancer and cluster agent;The molar ratio of the enhancer and cluster agent is (0.1-1) mol:(1-10) mmol;The enhancer is one or more than two combinations of 4,4-bis (5-methyl-2-benzoxazolyl) stilbene, 2,5-bis (5-tert-butyl-2-benzoxazolyl) thiofene, 4,4'-bis (2-sulfonic acid sodium phenylvinyl) biphenyl and 1,2-bis (5-methyl-benzoxazolyl) -ethylene;The cluster agent is one or more than two combinations of alginic acid, povidone, methyl vinyl ether-maleic anhydride copolymer and carrageenan.The fluorescent enhancement liquid with the above-mentioned fluorescent enhancement composition for tyramide signal amplification system as main component can enhance the effect of fluorescent signal amplification, reduce non-specific coloring.

The invention provides EB (Epstein-Barr) virus nucleic acid detection primers, a probe and a kit, according to a target sequence of an EB virus gene, the sequences of the primers and the probe in an asymmetric primer ERA detection system are designed and screened, and the ratio of upstream and downstream primers and an amplification reaction system are optimized, so that the EB virus nucleic acid sequence can be specifically identified, and the EB virus nucleic acid detection kit has the advantages of high specificity and high sensitivity. Non-specific binding with other irrelevant nucleic acids is reduced, so that the detection specificity is improved; meanwhile, efficient amplification of EB virus nucleic acid is realized, and the EB virus nucleic acid can be accurately detected even under the condition that the content of the virus nucleic acid is extremely low, so that the detection sensitivity and the amplification efficiency are improved.

This invention provides a chemiluminescence detection reagent, composition, kit, and method. The chemiluminescence detection reagent of this invention includes a first conjugate capable of specifically binding to a target molecule, the first conjugate being linked to a label, the label having at least two hydrophilic arms, each arm ending in a specific pairing agent. The reagent, composition, kit, and method of this invention exhibit high anti-interference properties and good sensitivity.